Header

UZH-Logo

Maintenance Infos

Publications for Eisele, G

Navigate back| Up a level
Export as
Group by:
Number of items: 21.

2016

Neidert, Marian C; Hostettler, Isabel C; Burkhardt, Jan-Karl; Mohme, Malte; Held, Ulrike; Kofmehl, Reto; Eisele, Günter; Woernle, Christoph M; Regli, Luca; Bozinov, Oliver (2016). The influence of intraoperative resection control modalities on survival following gross total resection of glioblastoma. Neurosurgical Review, 39(3):401-409.

Eisele, Günter. Defining targets for immunotherapy of glioblastoma. 2016, University of Zurich, Faculty of Medicine.

2015

Baumann-Vogel, H; Valko, P O; Eisele, G; Baumann, C R (2015). Impulse control disorders in Parkinson's disease: don't set your mind at rest by self-assessments. European Journal of Neurology, 22(4):603-609.

Wolpert, F; Happold, C; Reifenberger, G; Florea, A M; Deenen, R; Roth, P; Neidert, M C; Lamszus, K; Westphal, M; Weller, M; Eisele, G (2015). Interferon-β modulates the innate immune response against glioblastoma initiating cells. PLoS ONE, 10(10):e0139603.

2014

Neidert, Marian C; Leske, Henning; Matoscevic, Katja; Eisele, Günter; Rushing, Elisabeth; Sürücü, Oguzkan (2014). A 42-year-old male with a new onset generalized seizure. Brain Pathology, 24(1):99-100.

Wolpert, F; Tritschler, I; Steinle, A; Weller, M; Eisele, G (2014). A disintegrin and metalloproteinases 10 and 17 modulate the immunogenicity of glioblastoma-initiating cells. Neuro-Oncology, 16(3):382-391.

Tonder, Michaela; Eisele, Günter; Weiss, Tobias; Hofer, Silvia; Seystahl, Katharina; Valavanis, Antonios; Stupp, Roger; Weller, Michael; Roth, Patrick (2014). Addition of lomustine for bevacizumab-refractory recurrent glioblastoma. Acta Oncologica, 53(10):1436-1440.

Tonder, M; Weller, M; Eisele, G; Roth, P (2014). Carboplatin and Etoposide in Heavily Pretreated Patients with Progressive High-Grade Glioma. Chemotherapy, 60(5-6):375-378.

Eisele, G; Wick, A; Eisele, A C; Clément, P M; Tonn, J; Tabatabai, G; Ochsenbein, A; Schlegel, U; Neyns, B; Krex, D; Simon, M; Nikkhah, G; Picard, M; Stupp, R; Wick, W; Weller, M (2014). Cilengitide treatment of newly diagnosed glioblastoma patients does not alter patterns of progression. Journal of Neuro-Oncology, 117(1):141-145.

Lemke, Dieter; Weiler, Markus; Blaes, Jonas; Wiestler, Benedikt; Jestaedt, Leonie; Klein, Ann-Catherine; Löw, Sarah; Eisele, Günter; Radlwimmer, Bernhard; Capper, David; Schmieder, Kirsten; Mittelbronn, Michel; Combs, Stephanie E; Bendszus, Martin; Weller, Michael; Platten, Michael; Wick, Wolfgang (2014). Primary Glioblastoma Cultures: Can Profiling of Stem Cell Markers Predict Radiotherapy Sensitivity? Journal of Neurochemistry, 131(2):251-264.

Roth, P; Stupp, R; Eisele, G; Weller, M (2014). Treatment of primary CNS lymphoma. Current Treatment Options in Neurology, 16(1):277.

2013

Eisele, G; Wolpert, F; Decrey, G; Weller, M (2013). APO010, a synthetic hexameric CD95 ligand, induces death of human glioblastoma stem-like cells. Anticancer Research, 33(9):3563-3571.

Eisele, G; Weller, M (2013). Targeting apoptosis pathways in glioblastoma. Cancer Letters, 332(2):335-345.

2012

Wolpert, F; Roth, P; Lamszus, K; Tabatabai, G; Weller, M; Eisele, G (2012). HLA-E contributes to an immune-inhibitory phenotype of glioblastoma stem-like cells. Journal of Neuroimmunology, 250(1-2):27-34.

Roth, P; Eisele, G; Weller, M (2012). Immunology of brain tumors. In: Aminoff, M; Boller, F; Swaab, D. Neuro-Oncology. Amsterdam: Elsevier, 45-51.

Schreglmann, S R; Gantenbein, A R; Eisele, G; Baumann, C R (2012). Transdermal rotigotine causes impulse control disorders in patients with restless legs syndrome. Parkinsonism & Related Disorders, 18(2):207-209.

2011

Eisele, G; Roth, P; Hasenbach, K; Aulwurm, S; Wolpert, F; Tabatabai, G; Wick, W; Weller, M (2011). APO010, a synthetic hexameric CD95 ligand, induces human glioma cell death in vitro and in vivo. Neuro-Oncology, 13(2):155-164.

Roth, P; Wischhusen, J; Happold, C; Chandran, P A; Hofer, S; Eisele, G; Weller, M; Keller, A (2011). A specific miRNA signature in the peripheral blood of glioblastoma patients. Journal of Neurochemistry, 118(3):449-457.

2010

Miller, J; Eisele, G; Tabatabai, G; Aulwurm, S; von Kürthy, G; Stitz, L; Roth, P; Weller, M (2010). Soluble CD70: a novel immunotherapeutic agent for experimental glioblastoma. Journal of Neurosurgery, 113(2):280-285.

2009

Roth, P; Kissel, M; Herrmann, C; Eisele, G; Leban, J; Weller, M; Schmidt, F (2009). SC68896, a novel small molecule proteasome inhibitor, exerts antiglioma activity in vitro and in vivo. Clinical Cancer Research, 15(21):6609-6618.

2008

Eisele, G; Roth, P; Wick, W; Weller, M (2008). MGMT in der klinischen Praxis. Onkologie Heute, 6(4):32-39.

This list was generated on Thu Apr 25 17:47:10 2019 CEST.